Patterns of long acting injectable antipsychotic use and associated clinical factors in schizophrenia among 15 Asian countries and region

Chao Tian Tang, Ee Cheong Chua, Qian Hui Chew, Yan Ling He, Tian Mei Si, Helen F.K. Chiu, Yu Tao Xiang, Takahiro A. Kato, Shigenobu Kanba, Naotaka Shinfuku, Min Soo Lee, Seon Cheol Park, Yong Chon Park, Mian Yoon Chong, Shih Ku Lin, Shu Yu Yang, Adarsh Tripathi, Ajit Avasthi, Sandeep Grover, Roy A. KallivayalilPichet Udomratn, Kok Yoon Chee, Andi J. Tanra, Md Golam Rabbani, Afzal Javed, Samudra Kathiarachchi, Dulshika Waas, Wing Aung Myint, Norman Sartorius, Van Cuong Tran, Kim Viet Nguyen, Chay Hoon Tan, Ross J. Baldessarini, Kang Sim

Research output: Contribution to journalArticle

Abstract

Introduction: Patterns of clinical use of long-acting injectable (LAI) antipsychotic drugs in many countries, especially in Asia, for treatment of patients diagnosed with chronic psychotic disorders including schizophrenia are not well established. Methods: Within an extensive research consortium, we evaluated prescription rates for first- (FGA) and second-generation antipsychotic (SGA) LAI drugs and their clinical correlates among 3557 subjects diagnosed with schizophrenia across 15 Asian countries and region. Results: Overall, an average of 17.9% (638/3557; range: 0.0%-44.9%) of treated subjects were prescribed LAI antipsychotics. Those given LAI vs orally administered agents were significantly older, had multiple hospitalizations, received multiple antipsychotics more often, at 32.4% higher doses, were more likely to manifest disorganized behavior or aggression, had somewhat superior psychosocial functioning and less negative symptoms, but were more likely to be hospitalized, with higher BMI, and more tremor. Being prescribed an FGA vs SGA LAI agent was associated with male sex, aggression, disorganization, hospitalization, multiple antipsychotics, higher doses, with similar risks of adverse neurological or metabolic effects. Rates of use of LAI antipsychotic drugs to treat patients diagnosed with schizophrenia varied by more than 40-fold among Asian countries and given to an average of 17.9% of treated schizophrenia patients. We identified the differences in the clinical profiles and treatment characteristics of patients who were receiving FGA-LAI and SGA-LAI medications. Discussion: These findings behoove clinicians to be mindful when evaluating patients' need to be on LAI antipsychotics amidst multifaceted considerations, especially downstream adverse events such as metabolic and extrapyramidal side effects.

Original languageEnglish
JournalAsia-Pacific Psychiatry
DOIs
Publication statusAccepted/In press - 2020

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Patterns of long acting injectable antipsychotic use and associated clinical factors in schizophrenia among 15 Asian countries and region'. Together they form a unique fingerprint.

  • Cite this

    Tang, C. T., Chua, E. C., Chew, Q. H., He, Y. L., Si, T. M., Chiu, H. F. K., Xiang, Y. T., Kato, T. A., Kanba, S., Shinfuku, N., Lee, M. S., Park, S. C., Park, Y. C., Chong, M. Y., Lin, S. K., Yang, S. Y., Tripathi, A., Avasthi, A., Grover, S., ... Sim, K. (Accepted/In press). Patterns of long acting injectable antipsychotic use and associated clinical factors in schizophrenia among 15 Asian countries and region. Asia-Pacific Psychiatry. https://doi.org/10.1111/appy.12393